Maxim Group Reaffirms Hold Rating for NovaBay Pharma (NBY)
NovaBay Pharma (NYSE:NBY) traded down 5.79% on Thursday, reaching $4.39. The company had a trading volume of 126,040 shares. The stock’s market capitalization is $49.39 million. The firm has a 50 day moving average price of $3.57 and a 200-day moving average price of $2.73. NovaBay Pharma has a 12 month low of $1.75 and a 12 month high of $9.50.
NovaBay Pharma (NYSE:NBY) last released its quarterly earnings results on Thursday, August 11th. The company reported ($0.36) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.30) by $0.06. The company earned $2.70 million during the quarter, compared to analysts’ expectations of $1.76 million. Analysts forecast that NovaBay Pharma will post ($1.77) earnings per share for the current fiscal year.
NovaBay Pharma Company Profile
NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.
Receive News & Ratings for NovaBay Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharma and related companies with MarketBeat.com's FREE daily email newsletter.